Food and Drug Administration approved this peptide in June 2019, highlighting its safety and efficacy, which can help women feel more confident in considering this treatment
By combining compounded GLP-1 access with optional genetic predisposition screening, PlexusDx enables patients to evaluate both clinical factors (baseline health, contraindications) and biological context (genetic variants influencing GLP-1 signaling) before starting treatment
However, so far across studies with GLP1R agonists , cardiovascular measurements such as blood pressure have seen improvements in general, with no significant increases in adverse cardiovascular effects seen in patients even after 2 years (In fact, decreases were seen), suggesting that the cardiovascular benefits of decreased body weight may overcome any potential harm that increases in heart rate by GLP1R agonists may cause
Ensure you get enough sleep each night
TK, AT and EB conceived and designed the study